Editorial Comment

No AccessJournal of UrologyEditorial Comment2 Aug 2024Editorial CommentThis article comments on the following:miR-371a-3p Predicting Viable Tumor in Patients Undergoing Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer: The SWENOTECA-MIR Study Kshitij Pandit, Jane Smitham, Sarah Murray, and Aditya Bagrodia Kshitij PanditKshitij Pandit https://orcid.org/0009-0003-0105-4430 University of California, San Diego School of Medicine, La Jolla, California , Jane SmithamJane Smitham University of California, San Diego School of Medicine, La Jolla, California , Sarah MurraySarah Murray University of California, San Diego School of Medicine, La Jolla, California , and Aditya BagrodiaAditya Bagrodia https://orcid.org/0000-0002-3358-1193 University of California, San Diego School of Medicine, La Jolla, California University of Texas Southwestern Medical Center, Dallas, Texas Editorial Board member, The Journal of Urology View All Author Informationhttps://doi.org/10.1097/JU.0000000000004176AboutFull TextPDF Cite Export CitationSelect Citation formatNLMAMAIEEEACMAPAChicagoMLAHarvardTips on citation downloadDownload citationCopy citation ToolsAdd to favoritesTrack Citations ShareFacebookLinked InTwitterEmail "Editorial Comment." The Journal of Urology, Publish Ahead of Print, pp. REFERENCES 1. ; SWENOTECA Working Group. miR-371a-3p predicting viable tumor in patients undergoing retroperitoneal lymph node dissection for metastatic testicular cancer: the SWENOTECA-MIR study. J Urol. 2024; 212(5):000-000. doi: 10.1097/JU.0000000000004164 Link, Google Scholar 2. Serum microRNA-371a-3p levels predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection. Eur Urol. 2020; 77(2):290-292. doi: 10.1016/j.eururo.2019.10.005 Crossref, Medline, Google Scholar 3. Serum miRNA predicts viable disease after chemotherapy in patients with testicular nonseminoma germ cell tumor. J Urol. 2018; 200(1):126-135. doi: 10.1016/j.juro.2018.02.068 Link, Google Scholar 4. Refining the serum miR-371a-3p test for viable germ cell tumor detection. Sci Rep. 2023; 13(1):10558. doi: 10.1038/s41598-023-37271-1 Crossref, Medline, Google Scholar © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsRelated articlesJournal of Urology25 Jul 2024miR-371a-3p Predicting Viable Tumor in Patients Undergoing Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer: The SWENOTECA-MIR Study Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Kshitij Pandit University of California, San Diego School of Medicine, La Jolla, California More articles by this author Jane Smitham University of California, San Diego School of Medicine, La Jolla, California More articles by this author Sarah Murray University of California, San Diego School of Medicine, La Jolla, California More articles by this author Aditya Bagrodia University of California, San Diego School of Medicine, La Jolla, California University of Texas Southwestern Medical Center, Dallas, Texas Editorial Board member, The Journal of Urology More articles by this author Expand All Advertisement PDF downloadLoading ...